JOSÉ
HERNÁNDEZ QUERO
Investigador desde 2024
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (31)
2023
-
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
Frontiers in Cellular and Infection Microbiology, Vol. 13
2022
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19
Frontiers in Immunology, Vol. 13
2021
-
HIV/HBV coinfection: Temporal trends and patient characteristics, Spain, 2002 to 2018
Eurosurveillance, Vol. 26, Núm. 25
-
Hemophagocytic lymphohistiocytosis associated with Leishmania: A hidden passenger in endemic areas
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 4, pp. 188-191
2020
-
Dalbavancin is a novel antimicrobial against Gram-positive pathogens: Clinical experience beyond labelled indications
European Journal of Hospital Pharmacy, Vol. 27, Núm. 5, pp. 310-312
2019
2018
-
High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial
PLoS ONE, Vol. 13, Núm. 4
-
Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
Open Forum Infectious Diseases, Vol. 5, Núm. 1
-
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial
Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451
2017
-
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study
HIV Medicine, Vol. 18, Núm. 7, pp. 482-489
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens
PLoS ONE, Vol. 11, Núm. 2
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Characteristics of tuberculosis in the immigrant population in South Granada Health Area
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 3, pp. 166-172
-
Concomitant tuberculosis and lung cancer diagnosed by bronchoscopy
International Journal of Tuberculosis and Lung Disease, Vol. 19, Núm. 9, pp. 1027-1032
-
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2014
-
Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin
Osteoporosis International, Vol. 25, Núm. 6, pp. 1709-1715